StoneX Group’s CERo Therapeutics CERO Stock Holding History

StoneX Group’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8	Closed	-$1.55K	–	926
2024 Q3	$1.55K	Buy	+8	New	+$2.44K	﹤0.01%	375

Other funds holding CERO

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return

Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Selkirk Management Chatham, New Jersey $294M AUM 26.84% 1-Year Est. Return

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

StoneX Group's CERO Position: Q4 2024 in Review

StoneX Group sold out of CERo Therapeutics (CERO) in Q4 2024, closing a stake of 8 shares — an estimated $1.55K sold.

StoneX Group first reported a position in CERO in Q3 2024 and held it in 1 quarter. The position peaked at $1.55K in Q3 2024. 18 funds tracked by Wall St. Rank hold CERO as of Q4 2024.

StoneX Group reported no remaining CERo Therapeutics position as of Q4 2024 after selling out during the quarter.
StoneX Group sold 8 CERo Therapeutics shares in Q4 2024, an estimated $1.55K.
StoneX Group first reported a position in CERo Therapeutics in Q3 2024 and held it in 1 quarter.
StoneX Group's CERo Therapeutics position peaked at $1.55K in Q3 2024.
18 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2024.

Based on StoneX Group's 13F filing for Q4 2024, filed 12 Feb 2025.